Novo Nordisk ( NVO ) announced on Monday that they will end their collaboration with Hims & Hers Health ( NYSE: HIMS ), ending the immediate access to Wegovy, its weight loss medication, via NovoCare Pharmacy.
In late April, the FDA announced that the Wegovy shortage was over. Following this, Novo Nordisk started working with telehealth providers such as Hims & Hers to offer direct access to their weight management medication via injections.
After over a month of collaboration, Novo Nordisk stated that Hims & Hers Health has failed to adhere to legal requirements prohibiting the bulk selling of compounded medications under the deceptive premise of "customization." This raises significant questions regarding patient safety.
"We plan to partner with telehealth firms that emphasize patient protection when offering direct access to Wegovy. Should any company partake in unlawful compounding activities jeopardizing American health, we will respond accordingly," stated Dave Moore, Executive Vice President for U.S. operations at Novo Nordisk.
The stock price of Hims & Hers has decreased. 24% premarket post this news.
Novo Nordisk reported that an inquiry revealed that fake semaglutide products distributed through telehealth services and compound pharmacies were found to include active pharmaceutical components obtained from unauthorized overseas suppliers based in China.
The firm additionally referenced a study from the Brookings Institution suggesting that the FDA has not sanctioned or approved the production methods used by any of these international suppliers for semaglutide. Furthermore, the FDA has neither assessed nor endorsed the quality of the semaglutide produced by them.
Further details on Novo Nordisk, Hims & Hers Health
- Novo Nordisk: The Former GLP-1 Pioneer Is Currently a Strong Bargain
- Novo Nordisk and Its Actual Worth
- Why The Hims & Hers Health Campaign Has Potential for Growth
- Novo releases Phase 1/2 trial findings for new obesity treatment, amycretin.
- Lilly, Novo, and Amgen anticipate crucial obesity trial outcomes during the current ADA meeting.